Information may be obtained or stored in your browser by cookies when you access the Website. This information is related to the user, the user settings or device. It is primarily used to ensure the site functions as expected by the user. We respect your right to privacy. Therefore, you can select to not allow some types of cookie. Please click on the different category headings to check the details and then change our default settings.
Strictly Necessary Cookies are cookies that are essential for this site to function properly. Strictly Necessary Cookies do not store information that can identify individuals. Strictly Necessary Cookies are used to view this site. Therefore, you cannot refuse the use of Strictly Necessary Cookies from these cookie settings. However, you can refuse the use of Strictly Necessary Cookies from the settings of your browser at any time. Please note that parts of the site may not function if you refuse the use of Strictly Necessary Cookies.
This site uses the following Strictly Necessary Cookies.
Cookie name: gdprCookieEn
Cookie name: optGA
Cookie name: optPardot
Net sales under the current Medium-term Business Plan KAYAKU Vision 2025 (KV25) continued to set new records until FY2024, the third year of the plan, and are expected to exceed the target of 230 billion yen in FY2025.
Meanwhile, operating income is trending below the target for each fiscal year due to factors such as soaring raw material prices, higher fixed costs, and the occurrence of license fees at the Life Science Business Unit. In FY2025, the final fiscal year of KV25, we will aim to achieve an operating income of 20 billion yen, which was the forecast as of May. At the same time, we will strengthen initiatives, such as passing on the costs to prices, and strive to get as close to the target as possible.
For return on equity (ROE), we will work toward achieving the target of 8% together with our capital policy. We will also continue measures toward achieving the medium-term target of a return on invested capital (ROIC) of 10% through company-wide capital efficiency improvement initiatives.
| Net sales | Operating income | ROE | ROIC | ||||
|---|---|---|---|---|---|---|---|
| Goals 230 billion yen | Goals 26.5 billion yen | Goals 8% or more | Goals 10% or more | ||||
| FY2024 results 222.6 billion yen | Self-evaluation ○ | FY2024 results 20.4 billion yen | Self-evaluation △ | FY2024 results 6.5% | Self-evaluation × | FY2024 results 7.1% | Self-evaluation △ |
Reduce by 46% in FY2030
(Compared to FY2019)
Achieve by FY 2050
Providing environmentally friendly semiconductor materials that contribute to next-generation communications and digital transformation (DX)
Providing products that ensure safety and security in the mobility field
Contributing to the improvement of QOL Providing a stable supply of pharmaceuticals
Providing safe agro-products to meet global food needs
Increasing customer satisfaction Human rights due diligence to business partners
Improve employee satisfaction Promotion of diversity
(Percentage of female managers over 10%, etc.)
The Nippon Kayaku Group pursues management that is strong to market changes through several business units. In the past, when the Safety Systems Business shifted to automotive safety components from its previous form as the industrial pyrotechnic business, it was supported by the Functional Chemicals Business and Pharmaceuticals Business until stable income was achieved.
Currently, the Safety Systems Business is growing. It is under the Mobility & Imaging Business Unit, which has become an earning pillar of Nippon Kayaku. Meanwhile, the Pharmaceuticals Business—which is under the Life Science Business Unit—is in a business environment where its key products of generic drugs and biosimilars are easily affected by drug pricing revisions. Therefore, we invest in the new drug launches and such to improve the earning power of the Pharmaceuticals Business and use earnings from the other two business units to invigorate the Life Science Business Unit to seek overall growth for the Nippon Kayaku Group into the future.
We have clarified the positioning of the product groups in each business unit by evaluating and categorizing them in terms of growth and attractiveness of the market as well as profitability and competitiveness. We maximize cash generation by appropriately allocating management resources. At the same time, for product groups that need to improve profitability, we strive to keep their share of company-wide net sales to 2% or lower, such as by thoroughly searching for ways to improve profitability or withdrawing from those for which improvement is difficult.
Growth Outlook from 2023 to 2030
Categorization as of May 2025
| Important |
|
|---|---|
| Novel and future prospects |
|
| Foundation |
|
| Earning power amelioration |
|
Toward the next medium-term corporate plan, it is necessary to set high targets to achieve sustainable growth after fully reflecting on the reasons leading to underachievement of KV25. Therefore, we plan to set the Nippon Kayaku Group’s vision for 2035 as an ambitious long-term vision and formulate the medium-term corporate plan by back casting from 2035. The period until 2035 will be split into three phases, and the new medium-term corporate plan for Phase I, which spans FY2026 to FY2028, will be announced when we present our financial results for FY2025 (scheduled for May 2026).